- Home
- HWC vs GRFS Comparison
HWC vs GRFS Comparison
Compare HWC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWC
- GRFS
- Stock Information
- Founded
- HWC 1883
- GRFS 1940
- Country
- HWC United States
- GRFS Spain
- Employees
- HWC N/A
- GRFS N/A
- Industry
- HWC Major Banks
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- HWC Finance
- GRFS Health Care
- Exchange
- HWC Nasdaq
- GRFS Nasdaq
- Market Cap
- HWC 5.2B
- GRFS 5.1B
- IPO Year
- HWC N/A
- GRFS 2006
- Fundamental
- Price
- HWC $51.86
- GRFS $6.96
- Analyst Decision
- HWC Buy
- GRFS
- Analyst Count
- HWC 9
- GRFS 0
- Target Price
- HWC $61.78
- GRFS N/A
- AVG Volume (30 Days)
- HWC 758.4K
- GRFS 1.1M
- Earning Date
- HWC 04-15-2025
- GRFS 01-01-0001
- Dividend Yield
- HWC 3.51%
- GRFS N/A
- EPS Growth
- HWC 17.33
- GRFS 283.33
- EPS
- HWC 5.28
- GRFS 0.24
- Revenue
- HWC $1,387,633,000.00
- GRFS $7,467,006,939.00
- Revenue This Year
- HWC $10.62
- GRFS $8.45
- Revenue Next Year
- HWC $5.93
- GRFS $7.08
- P/E Ratio
- HWC $9.93
- GRFS $33.81
- Revenue Growth
- HWC 5.03
- GRFS 9.41
- 52 Week Low
- HWC $41.56
- GRFS $5.79
- 52 Week High
- HWC $62.40
- GRFS $9.96
- Technical
- Relative Strength Index (RSI)
- HWC 41.35
- GRFS 32.24
- Support Level
- HWC $51.01
- GRFS $7.13
- Resistance Level
- HWC $54.73
- GRFS $7.81
- Average True Range (ATR)
- HWC 1.37
- GRFS 0.19
- MACD
- HWC 0.24
- GRFS -0.13
- Stochastic Oscillator
- HWC 44.59
- GRFS 4.69
About HWC Hancock Whitney Corporation
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations and individuals and provides its customers access to investment advisory and brokerage products.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.